• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA to release monthly adverse event reports

EMA to release monthly adverse event reports

July 13, 2011
CenterWatch Staff

The EMA will start producing monthly adverse event reports for the public as part of its plans to open up access to drug information, according to InPharm.

The European regulator will release safety reports for all centrally authorized medicinal products by the end of 2011, featuring summarized information from the EMA’s EudraVigilance database. It will be extended to searchable reports for all medicines by the end of 2012.

The EMA also plans to give access to new tools to allow the detection and analysis of signals on adverse reactions to human medicines by 2015, subject to having the budget for it.

The agency said in a statement it would also “consider providing access to data for research purposes on a case-by-case basis, in line with its objective of protecting public health.”

The EMA agreed to give greater access to documents on medicines after heavy criticism last year from the European Ombudsman.

In May 2010, the European Ombudsman, led by P. Nikiforos Diamandouros, investigated complaints about E.U. bodies, including the EMA. In one case, the ombudsman focused on an Irish patient who in 2008 had his request for information on the adverse drug reactions for Roche’s acne medicine Roaccutane turned down by the regulator.

Diamandouros called on the EMA to give access to the relevant documents, especially those on the reactions seen in Roaccutane, in the name of patient safety. In June he said the body should grant access to blocked clinical study reports and trial protocols for three anti-obesity drugs, after new safety concerns were raised about the drugs’ link to suicidal thoughts and depression.

The EMA had long argued that it could not disclose such documents because of the risk to confidentiality, and that the publication of such documents could result in people seeing data that was “misleading or unreliable.”

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing